Latest Biotechnology, Pharmaceutical and Healthcare News from Xconomy

00:16 EDT 21st March 2019 | BioPortfolio

Here are the most relevant search results for "Xconomy" found in our extensive news archives from over 250 global news sources.

More Information about Xconomy on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Xconomy for you to read. Along with our medical data and news we also list Xconomy Clinical Trials, which are updated daily. BioPortfolio also has a large database of Xconomy Companies for you to search.

Showing News Articles 1–25 of 725 from Xconomy

Wednesday 20th March 2019

Corza Health Emerges Led by Former NuVasive, GreatCall Executives

A Chicago-based private equity firm has tapped the former head of NuVasive and finance chief of GreatCall to start a new healthcare company in San Diego. The company, Corza Health, is headed by Greg Lucier, most recently CEO at NuVasive, and backed by the PE firm, GTCR, with money from its $5.25 billion Fund XII. […]

As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround

A decade ago, Kevin Conroy took the CEO job at Exact Sciences, a cancer diagnostic firm on the brink of death. Five years later, the FDA greenlit the company’s first product, Cologuard, which marked the first non-invasive, stool-based DNA screening test approved for detecting colorectal cancer. In the five years since then, Exact (NASDAQ: EXAS) […]

Genentech’s Lieu Jumps to NGM Bio for Chief Medical Officer Post

Hsiao Lieu has been appointed senior vice president and chief medical officer of NGM Biopharmaceuticals. Lieu is joining South San Francisco, CA-based NGM from Genentech, where he was vice president of early clinical development. NGM has a five-year research partnership with Merck (NYSE: MRK), which recently exercised its option to acquire rights to an experimental NGM […]

Ex-Bayer Exec Adrian Percy Named Finistere Chief Technology Officer

Finistere Ventures has appointed Bayer veteran Adrian Percy to serve as chief technology officer of the San Diego-based venture capital firm. Percy, the former head of research and development for Bayer’s crop science division, will be based in a new Finistere office opening in the Research Triangle Park region of North Carolina. Finistere also said […]

Pfizer Bolsters Gene Therapy Position with $51M Vivet Deal

Pfizer this morning added to its methodical push into the gene therapy field, paying $51 million for a 15 percent stake in Vivet Therapeutics and the option to buy the Parisian biotech in the future. Vivet is developing an experimental gene therapy, VTX-801, for the rare genetic disorder Wilson’s disease, which causes a potentially deadly […]

Flagship Reloads With $824M For Latest Growth Capital Fund

Flagship Pioneering, one of the Boston area’s top biotech company creators, has closed a new $824 million fund to help fuel the growth of its startups. The new fund—Special Opportunities Fund II—will complement the cash the firm uses to start its companies, much like the $285 million “Special Opportunities” fund the firm announced in 2016. In […]

Tuesday 19th March 2019

FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take

The FDA has just made brexanolone (Zulresso) the first medicine approved specifically for post-partum depression, a potentially devastating disorder that afflicts roughly one in every seven new mothers in the U.S., according to the American Psychological Association Now the drug’s owner, Sage Therapeutics (NASDAQ: SAGE), of Cambridge, MA, must convince doctors to prescribe and new […]

Urovant Bladder Drug Hits Test Goals But Can’t Outpace Generic Rival

Urovant Sciences says its experimental drug for overactive bladder could offer advantages compared to an FDA-approved treatment marketed by Astellas Pharma. But late-stage clinical results released Tuesday raise questions whether Urovant can persuade doctors to prescribe it instead of a much cheaper generic competitor. Irvine, CA-based Urovant (NASDAQ: UROV) said Tuesday that its drug vibegron [&#...

Monday 18th March 2019

Paratek Pharma’s CFO Pagán to Leave for Job at an Early-Stage Biotech

Douglas Pagán, chief financial officer of Paratek Pharmaceuticals (NASDAQ: PRTK) since 2017, is resigning to take a role at an undisclosed early-stage biopharmaceutical company. The Boston company said Monday that Pagán’s last day will be April 5. He has entered into a consulting agreement through Dec. 23 to help with the transition of his responsibilities […]

Amgen’s Grauer Joins Corcept Therapeutics as Chief Medical Officer

Corcept Therapeutics (NASDAQ: CORT) has appointed Andreas Grauer to serve as chief medical officer. Grauer comes to Menlo Park, CA-based Corcept from Amgen (NASDAQ: AMGN), where he was vice president of global development. Corcept develops drugs that modulate a hormone called cortisol to treat metabolic and psychiatric disorders, as well as cancer. Corcept has already […]

The Role of the Student Engineer in Medicine and Innovation

The last 50 years have seen many great technical advances in medical treatments, ranging from drug delivery and imaging to skin grafts and prosthetics. These advances—both large and small—have drawn on many fields and have transformed patient care. When examining the current state of clinical technology, the focus is naturally on the technology and its […]

Dermira Shares Soar After Eczema Drug Hits Goal of Mid-Stage Study

An experimental drug developed by Dermira to treat atopic dermatitis has hit the main goal of its mid-stage study, helping to build a case that the injectable treatment could measure up against a drug from Regeneron Pharmaceuticals and Sanofi. Atopic dermatitis is the most common and severe form of eczema, an inflammatory condition that leads […]

JLabs’ Luby Takes the Reins at TMC Innovation Institute in Houston

Houston—Tom Luby, the head of JLabs in Houston, has been named the new director of the Texas Medical Center’s Innovation Institute, the center announced Monday morning. Luby takes over the innovation institute three months after former director Erik Halvorsen left the role. Luby is already a known presence around the TMC innovation building thanks to […]

Friday 15th March 2019

Servier Licenses CureMatch Tech for Custom Cancer Drug Treatments

A global pharmaceutical company based in France has licensed software developed by San Diego digital health startup CureMatch that aims to help cancer doctors customize the combination of drugs they prescribe to patients based on mutations in cancer DNA. CureMatch was founded in 2015 to commercialize technology developed at the UC San Diego Moores Cancer […]

Illumina’s Michael Ball Joins Contextual Genomics as CEO

Cancer genomics company Contextual Genomics has appointed Michael Ball to serve as its CEO. Ball comes to the Vancouver, BC-based company from Illumina (NASDAQ: ILMN), where he was global vice president commercial, informatics. Ball was previously CEO of GenoLogics Life Sciences Software, which was acquired by Illumina in 2015. Contextual Genomics develops molecular tests that […]

Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More

While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on the Summit, NJ, drug maker. In the early 2000s, before the FDA approved Celgene’s flagship multiple myeloma drug lenalidomide (Revlimid), Novartis (NYSE: NVS […]

WI Watchlist: Foxconn Fund, UW Accelerator, MSOE A.I. Hall & More

It’s time to catch up on Wisconsin innovation news: —Jason Franklin will manage the Wisconn Valley Venture Fund, a $100 million fund formed last August by Foxconn Technology Group and three leading Wisconsin businesses and organizations: Advocate Aurora Health, Northwestern Mutual, and Johnson Controls (NYSE: JCI). Foxconn, a Taiwanese manufacturing giant, has said it’s building ...

Thursday 14th March 2019

C4 Therapeutics Taps NIBR’s Crystal for Chief Medical Officer Post

Adam Crystal has been appointed chief medical officer of C4 Therapeutics. Crystal comes to the Watertown, MA-based biotech from the Novartis Institutes for BioMedical Research (NIBR), where he led several oncology programs. Before working at NIBR, Crystal was a medical oncologist at Massachusetts General Hospital. C4 is developing drugs that treat disease through protein degradation, […]

Gene Therapy Boom, Cracking Alzheimer’s: What’s Hot on May 21

Our annual half-day life sciences variety show, “What’s Hot in Biotech,” is back. Join Xconomy on May 21 at Bristol-Myers Squibb’s brand new offices in Kendall Square for a series of candid discussions, in a variety of formats, on some of the topics that will shape the healthcare landscape of tomorrow—from the volatile macro-environment to […]

Wednesday 13th March 2019

Tenaya Taps Whittemore Tingley for Chief Medical Officer

Whittemore Tingley has been appointed chief medical officer of Tenaya Therapeutics. Tingley comes to the South San Francisco, CA, biotech from Cytokinetics (NASDAQ: CYTK), where he was vice president of clinical research, cardiology. Tenaya spun out of the nonprofit Gladstone Institutes in 2016 to develop regenerative medicine treatments for heart failure.

Blood Test Study Meets Goal, Validates Epic’s Prostate Cancer Target

Epic Sciences has commercialized a blood test that can predict how likely a patient with late-stage prostate cancer treated with hormones is likely to respond to an additional course of such therapy. Now, the San Diego-based company has additional data that it says supports use of its tests to determine when not to use hormone […]

Nerissa Kreher Leaves Avrobio for Tiburio Chief Medical Officer Post

Tiburio Therapeutics has appointed Nerissa Kreher to the newly created position of chief medical officer. Kreher held that post at her previous company, Avrobio (NASDAQ: AVRO). Her experience also includes positions at Shire, Zafgen (NASDAQ: ZFGN), and Alexion Pharmaceuticals (NASDAQ: ALXN). In January, Tibiurio launched from biotech accelerator Cydan, backed by $31 million in funding. […]

X4 Completes Reverse Merger with Arsanis, Looks Ahead to Phase 3 Test

X4 Pharmaceuticals is the latest biotech to join the public markets, but it didn’t follow the IPO path to get there. Cambridge, MA-based X4 said Wednesday that it completed its “reverse merger” with Arsanis (NASDAQ: ASNS). Such business combinations enable a privately held company to go public by merging with a publicly traded business. Shares […]

FDA Clears Aerie’s Combo Glaucoma Drug, But Will it Sell?

The FDA late Tuesday approved a new type of glaucoma drug from Aerie Pharmaceuticals that, in clinical testing, beat the generic eye drops known as prostaglandin analogues (PGAs) that are typically prescribed to slow the progression of the disease. Now Aerie (NASDAQ: AERI) will try to prove that the drug can overcome some of its […]

Nominations Are Open for the 2019 Xconomy Awards in Boston

John Maraganore, CEO of Alnylam Pharmaceuticals; Penny Heaton, CEO of the Bill & Melinda Gates Medical Research Institute; digital health leader Pear Therapeutics; and renowned women-in-science advocate and MIT professor emerita Nancy Hopkins. These outstanding leaders were among the winners of the 2018 Xconomy Awards, which celebrate the top people, companies, and organizations in Boston [&#...

Quick Search


News Quicklinks